Bellerophon Therapeutics Inc (BLPH)

[hedge_fun]

“We believe Bellerophon’s portable, userfriendly device, INOpulse, offers a competitive value proposition as adjuvant therapy for PAH patients already on long-term oxygen support. We take a reductionist approach here and argue that despite the business development potential of INOpulse in the larger indications (i.e., PH-COPD and PH-IPF), a price target of $5/share can be fully supported by INOpulse in PAH alone. We conservatively model for a worldwide peak revenue of $238M (we discount this by 66% to get $157M for our valuation) for INOpulse in PAH by the year 2023. Ahead of the readouts from the two Phase 2 studies of INOpulse in PH-COPD and PH-IPF on tap for 1H17 that may offer additional upside, as well as the interim readout from the Phase 3 INO-1 of INOpulse in PAH on tap for YE17, we are initiating coverage with a Buy rating.”

https://www.smarteranalyst.com/2017/01/20/stock-update-nasdaqblph-heres-bellerophon-therapeutics-inc-shares-20/